Back to top
more

Moderna (MRNA)

(Delayed Data from NSDQ)

$84.93 USD

84.93
2,385,980

+0.61 (0.72%)

Updated Aug 9, 2024 04:00 PM ET

After-Market: $85.09 +0.16 (0.19%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Sheraz Mian headshot

Top Analyst Reports for Cisco, CVS Health & Moderna

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Cisco Systems, Inc. (CSCO), CVS Health Corporation (CVS) and Moderna, Inc. (MRNA).

John Blank headshot

The Vaccines Are Here. Are We Out of the Woods Now?

by John Blank

It almost seems like we are just an appointment at the doctor's office away from opening up our economy again.

Sweta Killa headshot

Stocks to Track in December as Markets Peak

by Sweta Killa

December is likely to be filled with events or stock/sector specific news that could provide a boost to the stocks.

Biotech Stock Roundup: BIIB & SAGE Alliance, MRNA, BNTX Coronavirus Updates & More

by Zacks Equity Research

Collaborations, and pipeline and regulatory updates take centerstage in the biotech sector as Moderna (MRNA) and BioNTech (BNTX) provide key updates.

Sweta Killa headshot

After a Historic November, What Awaits ETFs in December?

by Sweta Killa

Let's delve into some of the major events of December and learn how to tap the opportune moments with ETFs.

Pfizer/BioNTech's COVID-19 Vaccine Gets Approval in U.K.

by Zacks Equity Research

Pfizer (PFE) and BioNTech's (BNTX) COVID-19 vaccine candidate becomes the first-ever vaccine to get authorization.

Encouraging News on COVID-19 Vaccine

by Zacks Equity Research

Encouraging News on COVID-19 Vaccine

Mark Vickery headshot

ADP Reports 307K New Jobs, Revisions Up

by Mark Vickery

307K new private-sector jobs was lower than expected, and beneath the upwardly revised 404K from October.

Sweta Killa headshot

5 International ETFs That Outstripped US Market in November

by Sweta Killa

November was a banner month for the global stock market despite the rising number of COVID-19 cases.

Cimarex Energy (XEC) Up 48.6% QTD: What's Behind the Rally?

by Zacks Equity Research

Improving oil prices on positive coronavirus vaccine results aid Cimarex (XEC).

Stock Market News for Dec 2, 2020

by Zacks Equity Research

U.S. stock markets closed higher on Tuesday on the back of optimism surrounding COVID-19 vaccine.

Pfizer/BioNTech Seek Marketing Nod for COVID-19 Vaccine in EU

by Zacks Equity Research

Pfizer (PFE) and BioNTech's (BNTX) COVID-19 vaccine candidate is 95% effective in final analysis.

Kinjel Shah headshot

Will Americans Get COVID-19 Vaccine Sooner Than Europeans?

by Kinjel Shah

Moderna (MRNA), and Pfizer (PFE)/BioNTech (BNTX) file for emergency use authorization of their COVID-19 vaccine candidates in Europe

Neena Mishra headshot

Small Cap ETFs Deliver Big Gains for Investors

by Neena Mishra

November was the best month ever for the Russell 2000 index

Sweta Killa headshot

5 Stocks in Dow ETF That Powered the Best Month Since 1987

by Sweta Killa

Amid rising COVID-19 cases, the Dow Jones wrapped up its best month in more than 30 years after hitting the major milestone of 30,000 for the first time last week.

Novavax (NVAX) Rises Despite U.S. Coronavirus Vaccine Study Delay

by Zacks Equity Research

Novavax (NVAX) to begin a phase III study on NVX-CoV2373, its COVID-19 vaccine candidate in the United States and Mexico in the coming weeks. Shares up.

The Zacks Analyst Blog Highlights: Amazon, Google, Zoom Video, Automatic Data Processing and Moderna

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Amazon, Google, Zoom Video, Automatic Data Processing and Moderna

Moderna (MRNA) Seeks Nod for Emergency Use of COVID-19 Vaccine

by Zacks Equity Research

Moderna's (MRNA) coronavirus vaccine achieves efficacy rate of 94.1% in primary efficacy analysis. The company files for Emergency Use Authorization to the FDA.

Capri Holdings, Edgewell Personal Care, Moderna, Novavax and Zoom Video highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

Capri Holdings, Edgewell Personal Care, Moderna, Novavax and Zoom Video highlighted as Zacks Bull and Bear of the Day

Company News for Dec 1, 2020

by Zacks Equity Research

Companies In The News Are: MRNA, NKLA, GM, SPGI, INFO, NJR

Ritujay Ghosh headshot

COVID-19 Vaccine Race Heats Up: Drugmarkers on Final Lap

by Ritujay Ghosh

Shares of Moderna, Inc. (MRNA), Pfizer, Inc. (PFE) and AstraZeneca plc (AZN) are poised for substantial gains on encouraging final-stage trial results.

Tirthankar Chakraborty headshot

Stellar November Paves the Way for a Solid December: 5 Picks

by Tirthankar Chakraborty

Growth-oriented stocks like General Motors (GM), Malibu Boats (MBUU) and LaZBoy (LZB) are likely to do well this month on vaccine optimism and Yellen's possible appointment as US Treasury Secretary.

Mark Vickery headshot

Markets Sell, November Overall Great; Plus ZM Q3 Beats

by Mark Vickery

Market indexes were down on this last trading day of November, though it still managed to be an historically strong month for stocks overall.

Positive Development on COVID-19 Vaccine Front

by Zacks Equity Research

Positive Development on COVID-19 Vaccine Front

Vertex (VRTX) Symkevi/Kalydeco Label Expansion Gets EU Nod

by Zacks Equity Research

Vertex (VRTX) gets European approval for label expansion of Symkevi and Kalydeco combination pill in cystic fibrosis patients aged six to 11.